884650-98-0

Mpro inhibitor N3 is a potent SARS-CoV-2 MPro inhibitor with an EC50 value of 16.77 μM. Mpro inhibitor N3 shows antiviral activities against HCoV-229E, FIPV, IBV and MHV-A59[1][2][3].

ChEBI: N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide is a tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2. It has a role as an antiviral agent, an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor and an anticoronaviral agent. It is a tripeptide, a member of isoxazoles, a member of pyrrolidin-2-ones and a benzyl ester.

Store at -20°C

[1] Jin Z, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 Jun;582(7811):289-293. DOI:10.1038/s41586-020-2223-y
[2] Yang H, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005 Oct;3(10):e324. DOI:10.1371/journal.pbio.0030324
[3] Xue X, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008 Mar;82(5):2515-27. DOI:10.1128/JVI.02114-07